The Medicines and Healthcare products Regulatory Agency (MHRA) has strengthened safety warnings for all botulinum toxin type A products following reports of rare cases of iatrogenic botulism. For aesthetic practitioners, this update reinforces the importance of using authorised products, maintaining robust prescribing and treatment protocols, and ensuring patients are fully informed about potential risks and warning signs.

MHRA strengthens botulinum toxin safety guidance

Botulinum toxin remains one of the most widely used aesthetic medicines, with millions of treatments performed globally for both cosmetic and medical indications. However, the MHRA has issued updated guidance following rare reports where the effects of botulinum toxin have spread beyond the intended treatment area, resulting in iatrogenic botulism — a serious and potentially life-threatening condition.

The updated warnings apply to all licensed botulinum toxin type A products authorised for use in the UK. Manufacturers are updating product information, including Patient Information Leaflets (PILs) and prescribing information, to highlight the risks and symptoms associated with toxin spread.

For aesthetic clinics, this update provides an opportunity to review existing safety processes and ensure that patient education, prescribing decisions and aftercare pathways remain aligned with best practice.

What is iatrogenic botulism?

Iatrogenic botulism refers to botulism caused as a result of a medical treatment or procedure.

In relation to botulinum toxin treatments, it can occur if the effects of the toxin extend beyond the intended area of injection. Although rare, the condition can affect the nervous system and may become medically serious if not recognised and treated promptly.

Botulinum toxin products are prescription-only medicines (POMs) in the UK and must only be supplied, prescribed and administered within appropriate regulatory frameworks.

Key symptoms practitioners should discuss with patients

The MHRA advises healthcare professionals to ensure patients understand the symptoms that require urgent medical attention.

These include:

• Difficulty swallowing
• Difficulty speaking or slurred speech
• Breathing difficulties or shortness of breath
• Muscle weakness
• Severe drooping of the upper eyelids
• Other signs consistent with wider toxin spread

Symptoms may develop within days following treatment but can, in some cases, appear up to four weeks later.

Clinics should ensure patients know who to contact if they experience concerning symptoms following treatment and should have clear escalation pathways in place.

What does the MHRA update mean for aesthetic practitioners?

The updated guidance does not mean that botulinum toxin treatments are unsafe when appropriately prescribed and administered.

Instead, it reinforces the clinical responsibilities of practitioners involved in botulinum toxin treatments, including:

1. Confirm products are authorised for UK use

Practitioners should ensure all botulinum toxin products used are licensed and sourced through legitimate, regulated supply chains.

The MHRA has specifically highlighted concerns around unlicensed and counterfeit products, which may not meet UK quality and safety standards and may increase the risk of serious adverse reactions.

2. Review prescribing and administration protocols

Clinics should ensure that:

• Patients receive appropriate consultations before treatment
• Medical history and contraindications are reviewed
• Treatment decisions are clinically justified
• Product-specific guidance is followed
• Appropriate doses and injection techniques are used
• Practitioners administering treatments are appropriately trained and competent

The MHRA advises prescribers to ensure anyone they authorise to administer botulinum toxin understands the relevant product guidance and safety information.

3. Strengthen patient communication and consent

Patient consent should include discussion of potential risks, including rare but serious complications.

Practitioners should ensure patients understand:

• The expected effects of treatment
• Possible side effects
• When symptoms may occur
• How to seek help if they have concerns after treatment

Updating consent forms, treatment information documents and aftercare advice may be appropriate following this guidance.

The importance of robust aftercare pathways

Effective aftercare is a key part of safe aesthetic practice.

Clinics should consider:

✅ Providing written aftercare information
✅ Ensuring patients know how to contact the clinic after treatment
✅ Having a process for recording and reviewing adverse events
✅ Escalating suspected serious reactions appropriately
✅ Reporting suspected adverse drug reactions through the MHRA Yellow Card scheme

Healthcare professionals and patients are encouraged to report suspected side effects through the Yellow Card system to support ongoing medicine safety monitoring.

Counterfeit and unlicensed products: a continued concern

The MHRA has reiterated the risks associated with botulinum toxin products obtained outside regulated supply chains.

Unlicensed or counterfeit products may have unknown ingredients, incorrect concentrations or storage issues, creating additional risks for patients.

For responsible clinics, maintaining transparent procurement processes and using authorised medicines from reputable suppliers remains a fundamental aspect of patient safety.

Supporting patient confidence in aesthetic medicine

Safety updates from regulators are an important part of maintaining public confidence in aesthetic treatments.

Responsible practitioners can help patients make informed decisions by:

• Explaining that serious complications are rare but possible
• Providing evidence-based information
• Avoiding exaggerated claims
• Prioritising clinical assessment over convenience
• Ensuring treatments take place within appropriate medical standards

A strong safety culture benefits both patients and the reputation of the wider aesthetics profession.

Reviewing your clinic’s safety processes

Following this MHRA update, clinics may wish to review:

Clinical documentation

• Are consultation notes comprehensive?
• Are risks and benefits clearly documented?
• Are treatment details accurately recorded?

Patient information

• Do current consent forms reflect updated safety information?
• Are aftercare instructions clear?
• Do patients know when to seek urgent help?

Product governance

• Are all products authorised for UK use?
• Are supply chains fully documented?
• Are storage and handling procedures compliant?

Team training

• Are all practitioners aware of the updated MHRA advice?
• Are emergency procedures regularly reviewed?
• Does the team understand the signs of possible toxin spread?

Final thoughts

The MHRA’s updated warnings serve as a reminder that patient safety must remain at the centre of aesthetic medicine.

Botulinum toxin continues to have an established role in cosmetic and medical treatments when used correctly. However, maintaining high standards of prescribing, product sourcing, practitioner training, patient communication and follow-up care is essential.

By reviewing clinical processes and keeping teams informed, aesthetic clinics can continue to deliver safe, responsible and trusted treatments.